company name
company description	{style:type=span|font-size=12px|color=#999999|font-family=Times New Roman}*Baxter International Inc.*{style}{style:type=span|color=#999999} *is a global healthcare company with 46,500 employees and 2007 sales of US$11.3 billion. Its headquarters is in Deerfield, Illinois. The company* makes a wide variety of medical products across its three divisions, including drugs and vaccines, dialysis equipment, and IV supplies. Its BioScience segment makes protein and plasma therapies to treat hemophilia and immune disorders, as well as vaccines and biological sealants used to close surgical wounds. Baxter is a leading maker of intravenous(IV) supplies and systems via its Medication Delivery segment; the segment also makes infusion pumps and inhaled anesthetics. Baxter's Renal division makes dialyzers and other products for the treatment of end-stage renal disease (ESRD). {style} {style:type=span|color=#999999}Resource: [http://en.wikipedia.org/wiki/Baxter_International]{style}
home page		parent company
company tags

 

 

Their Record

1.1.1.1.1 {style:type=span|font-size=12px}The environmental impact is clearly an important factor in their decision making process, and sustainability has been a priority. Baxter's commitment to sustainability spans three decades. Baxter Healthcare has been a leader in implementing the Green Suppliers Network. With all the attempts they have made, still more effort should be applied to their disposal processes. {style} 1.1.1.1.1 {style:type=span|font-size=12px}The company has been recognized by Innovest Strategic Value Advisors as one of the [Global 100 Most Sustainable Corporations in the World>http://www.prnewswire.com/] and by Corporate Responsibility Officer magazine as one of the 100 Best Corporate Citizens in the United States. Baxter is a member of the Center for Corporate Citizenship at Boston College, the Business Environmental Leadership Council of the Pew Center on Global Climate Exchange, the Chicago Climate Exchange, the U.S. EPA's Climate Leaders, the Ethics & Compliance Officer Association and Hospitals for a Healthy Environment. Baxter endorses the Ceres principles and is an organizational stakeholder of the Global Reporting Initiative.{style} 1.1.1.1.1 {style:type=span|font-size=12px}In 1997, Baxter Healthcare Corp was awarded a [certificate of excellen>http://yosemite.epa.gov/opa/admpress.nsf/b1ab9f485b098972852562e7004dc686/360f23638574ccdc852570d6005e7e01!OpenDocument]{style}{style:type=span|font-size=12px}[ce>http://yosemite.epa.gov/opa/admpress.nsf/b1ab9f485b098972852562e7004dc686/360f23638574ccdc852570d6005e7e01!OpenDocument] during Pollution Prevention Week observances by Environmental Protection Agency Region 5.{style} 1.1.1.1.1 {style:type=span|font-size=12px}In 2003, {style}{style:type=span|font-size=12px|font-family=Arial}Environmental Protection Agency (EPA){style} Regional Administrator presented a [National Environmental Performance Track Outreach Award>http://yosemite.epa.gov/opa/admpress.nsf/b1ab9f485b098972852562e7004dc686/22ad74df33df0ef68525715d006575e7!OpenDocument] to Baxter Healthcare Corporation of Puerto Rico-Aibonito. Baxter Healthcare Corporation was honored for their success in getting three businesses in Puerto Rico to join Performance Track and for their efforts to facilitate a partnership between the Puerto Rico Manufacturers Association and EPA. In Fall 2004, Baxter and seven other healthcare firms kicked off the program – a collaborative venture between industry, [EPA and the Department of Commerce>http://yosemite.epa.gov/opa/admpress.nsf/a883dc3da7094f97852572a00065d7d8/8347fe908b34fd80852570680076c8b3!OpenDocument]. The Green Suppliers Network works with large manufacturers like Baxter to engage their small and medium-sized suppliers in low-cost technical reviews focused on process improvement and pollution prevention. American corporations are increasingly calling for action on global warming, sensing a business opportunity in cutting greenhouse gases while hoping to shape regulations they believe are inevitable. This shift in corporate thinking was on display at a congressional hearing last week, where executives from large companies, [Baxter International Inc. included>http://www.corpwatch.org/article.php?id=12391], described how they were getting an early start on reducing greenhouse gas emissions -- something they believe they would be required to do sooner or later. Scorecard shows [Baxter Healthcare in Mountain Home, AR>http://www.scorecard.org/env-releases/facility.tcl?tri_id=72653BXTRH1900N#maps] ranked 50%-60% in noncancer (air and water) risk score, 60%-70% in recognized development toxicants, 70%-80% in cancer risk scores and air releases of recognized carcinogen, 80%-90% in air releases of recognized reproductive toxicants, which is unsatisfactory in all. [Baxter Healthcare in Guayama, PR>http://www.scorecard.org/env-releases/facility.tcl?tri_id=00654NQSTNROAD3#major_chemical_releases] also had a rather low overall ranking. Wall Street Journal states that in[1999 Baxter International Inc pledged to develop alternatives to phthalate-containing PVC>http://www.rachel.org/en/node/6589]. However, according to phthalate Information Centre Europe, [the annoucement was misconstrued>http://www.phthalates.com/index.asp?page=18]by certain environmental groups and the media. Baxter reiterated that in many applications, PVC would remain the material of choice. <table border="0" cellspacing="0" cellpadding="0" width="583"><tbody><tr><td bgcolor="#ffffff"> </td></tr><tr><td colspan="12" height="1" bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td colspan="12" height="1" bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td colspan="12" height="1" bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td colspan="12" height="1" bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td colspan="12" height="1" bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr><tr><td bgcolor="#ffffff"> </td></tr></tbody></table>

   

 

Their Record

1.1.1.1.1 {style:type=span|font-size=12px}We found that this company has taken some steps, but that doesn't take its impact on the global community seriously enough. Materials show that Baxter was engaged in certain lawsuits and problematic issues which undermined its reputation. Our research is what backs up the rating above.{style} 1.1.1.1.1 {style:type=span|font-size=12px}Baxter works closely with [governments worldwide on pandemic preparation>http://www.prnewswire.com/]. The company has delivered several million doses of CELVAPAN to various governments around the world. In 2006, Baxter entered into a pandemic preparedness contract with the Austrian Ministry of Health to supply 16 million doses of pandemic influenza vaccine in the event a pandemic is declared. The company also delivered a stockpile of two million doses of CELVAPAN to the U.K. Department of Health as part of an agreement announced in February 2006. To improve access to treatment in developing countries, Baxter also supports the World Health Organization's pandemic planning programs through participation in a planned international stockpile program.{style} 1.1.1.1.1 {style:type=span|font-size=12px}Baxter International is a member of the [free trade zones of oppression>http://www.multinationalmonitor.org/hyper/mm0993.html] in the Dominican Republic, which is to "get US law imposed and insist that the law be followed so that 'Federation of Fired People' can have freedom of assoication and collective bargaining."{style} {style:type=span|font-size=12px}Baxter is also working with the NIAID in partnership with Fisher BioServices Inc., and with the U.S. Department of Health and Human Services in partnership to further develop Vero cell culture-based candidate pandemic and seasonal influenza vaccines. Baxter is working with the U.S. Department of Health and Human Services, in partnership with DVC LLC, on a seasonal Phase III clinical trial that is currently underway in the United States and also plans to initiate a pandemic Phase I trial later this year in the United States with an H5N1 reverse genetic reassorted (RG) Indonesia strain vaccine. \\   {style} 1.1.1.1.1 {style:type=span|font-size=12px}In 2008 the quality of blood thinning products produced by Baxter{style} was brought into question when they were linked to 19 deaths in the US. Upon inspection one of the raw ingredients used by Baxter were found to be contaminated - between 5 and 20 percent - with a substance that was similar, but not identical, to the ingredient itself. Enough for them to be considered sub-potent and thus unsuitable for use. Baxter did not pick up on the contamination until after the FDA became involved. 1.1.1.1.1 {style:type=span|font-size=12px}Investigation into the contamination has focused on raw heparin{style} produced by [Changzhou Scientific Protein Laboratories>http://www.corpwatch.org/article.php?id=14934], a China based branch of Scientific Protein Laboratories, based in Waunakee, Wisconsin. The factory's products were also not certified by the FDA as safe for use in pharmaceutical products by Chinese FDA officials as Changzhou SPL was itself registered as a chemical company and not a drugs manufacturer.Baxter was proactive in raising the issue with the FDA and is co-operating fully in the investigation. 1.1.1.1.1 {style:type=span|font-size=12px}Dow Corning and other implant manufacturers - Baxter International included- reached [a settlement with plaintiffs’ attorneys in September 1994>http://www.multinationalmonitor.org/hyper/mm0595.html]. Under the terms of the settlement, a $4.23 billion trust would be established - $2 billion of which would be contributed by Dow Corning - to compensate victims: women who had silicone breast implants  and who experienced a host of ailments.{style}